The treatment of melanoma has been revolutionized over the past decade with the
development of effective molecular and immune targeted therapies. The great majority of …

Opinion statement Melanoma is the most aggressive of the cutaneous malignancies,
causing more than 9,000 deaths in the past year in the United States. Historically, systemic …

New drugs targeting the mitogen-activated protein kinase (MAPK) pathway have generated
striking clinical response in melanoma therapy. From the discovery of BRAF mutation in …

Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …

The development of novel treatments that selectively inhibit the RAS-RAF-MAPK pathway
represents a milestone in the history of melanoma treatment. BRAF mutations occur in …

The discovery and development of small molecule inhibitors of mutant BRAF kinase and
MEK kinase have revolutionized the care of patients with melanoma. When used as single …

The identification of driver mutations in melanoma has changed the field of cancer treatment.
BRAF and NRAS mutations are predominant in melanoma and lead to overactivation of the …

Treatment with BRAF inhibitors such as vemurafenib or dabrafenib in patients with
advanced BRAFV600 mutated melanoma has shown objective tumor responses in …

Over the past several years, management of advanced melanoma has been transformed by
the development and approval of novel therapeutic approaches. Genetically targeted …

BACKGROUND: Melanoma is an aggressive disease that accounts for approximately 75%
of skin cancer-related deaths. Historically, treatment options for patients with advanced …